In the next stage, we studied the expression of 13 stemness genes in 98 patients (TERT, OCT3, SMO, MYC, SNAI2, TGFBR1, KLF4, BMI1, VIM, FLT3, SMAD2, KLF1, and TGFβ1) with breast tumors before treatment and after NAC, and we compared the expression levels of these genes in patients with metastases (32 of 98) and without metastases (66 of 98). This evidence concerns the gene VIM and breast neoplasm.